Christopher Starr
Founder at MONOPAR THERAPEUTICS INC.
Net worth: 47 190 $ as of 2024-04-29
Profile
Christopher M.
Starr is the founder of Horizon Pharmaceutical LLC (founded in 2009), Monopar Therapeutics, Inc. (founded in 2014), BioMarin Pharmaceutical, Inc. (founded in 1997), and Raptor Pharmaceuticals Corp.
(founded in 2005).
He holds the title of Independent Director at Horizon Pharmaceutical LLC from 2015 to 2016, Executive Chairman at Monopar Therapeutics, Inc. from 2014 to present, and Chief Scientific Officer & Senior Vice President at BioMarin Pharmaceutical, Inc. He also served as a Director at Raptor Pharmaceuticals Corp.
from 2014 to 2016.
Dr. Starr's current job(s) include being the Chief Executive Officer at Raptor Discoveries, Inc. since 2005, Chairman at Thiogenesis Therapeutics, Inc., Chairman at Thiogenesis Therapeutics Corp.
since 2022, and Director at Glycomine, Inc. since 2016.
His former job(s) include being the Vice President-Research & Development at Glyko, Inc. from 1991 to 1998.
He also worked as an Associate at The National Research Council and National Institutes of Health.
Dr. Starr's education history includes a doctorate degree from SUNY Upstate Medical University and an undergraduate degree from Syracuse University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
MONOPAR THERAPEUTICS INC
0.43% | 2024-03-07 | 75,263 ( 0.43% ) | 47 190 $ | 2024-04-29 |
| 2022-12-07 | 0 ( -.--% ) | - $ | 2024-04-29 |
Christopher Starr active positions
| Companies | Position | Start |
|---|---|---|
| MONOPAR THERAPEUTICS INC. | Founder | 2014-11-30 |
| THIOGENESIS THERAPEUTICS, CORP. | Chairman | 2022-03-30 |
| Raptor Discoveries, Inc. | Chief Executive Officer | 2005-09-07 |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Director/Board Member | 2016-05-31 |
Former positions of Christopher Starr
| Companies | Position | End |
|---|---|---|
| RAPTOR PHARMACEUTICAL CORP | Founder | 2016-10-24 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Founder | 2016-09-30 |
| BIOMARIN PHARMACEUTICAL INC. | Founder | 2005-12-31 |
Glyko, Inc.
 Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Chief Tech/Sci/R&D Officer | 1997-12-31 |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Training of Christopher Starr
| Syracuse University | Undergraduate Degree |
| SUNY Upstate Medical University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| MONOPAR THERAPEUTICS INC. | Health Technology |
| THIOGENESIS THERAPEUTICS, CORP. | Finance |
| Private companies | 7 |
|---|---|
Glyko, Inc.
Glyko, Inc. Medical SpecialtiesHealth Technology Part of BioMarin Pharmaceutical, Inc., Glyko, Inc. discovers, develops, and commercializes carbohydrate enzyme therapeutics. The company is based in Novato, CA. Glyko was acquired by BioMarin Pharmaceutical, Inc. on October 08, 1998 for $14.50 million. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
| Raptor Discoveries, Inc. | |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
The National Research Council
 The National Research Council Miscellaneous Commercial ServicesCommercial Services The National Research Council provides science, technology and health policy consulting and advice. The company was founded in 1916 and is headquartered in Washington, DC. | Commercial Services |
National Institutes of Health
National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
- Stock Market
- Insiders
- Christopher Starr
